ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of "Moderate Buy" by Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six brokerages that are currently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $8.50.

ALXO has been the topic of several research analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of ALX Oncology in a research note on Wednesday, December 18th. Jefferies Financial Group lowered ALX Oncology from a "buy" rating to a "hold" rating and cut their price objective for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of ALX Oncology in a research note on Wednesday, December 18th.

Insider Buying and Selling at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the business's stock in a transaction on Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the acquisition, the director now owns 33,000 shares in the company, valued at approximately $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 14,443 shares of company stock valued at $23,309. Corporate insiders own 33.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALXO. Hsbc Holdings PLC purchased a new stake in ALX Oncology in the 2nd quarter worth approximately $63,000. AQR Capital Management LLC lifted its holdings in shares of ALX Oncology by 50.7% during the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock valued at $109,000 after buying an additional 6,080 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock valued at $50,000 after buying an additional 6,888 shares in the last quarter. Algert Global LLC acquired a new stake in ALX Oncology in the second quarter valued at approximately $249,000. Finally, GSA Capital Partners LLP bought a new stake in ALX Oncology in the third quarter worth approximately $88,000. Hedge funds and other institutional investors own 97.97% of the company's stock.

ALX Oncology Stock Performance

ALX Oncology stock traded up $0.11 during mid-day trading on Friday, hitting $1.74. 578,695 shares of the company's stock traded hands, compared to its average volume of 738,618. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology has a one year low of $1.19 and a one year high of $17.83. The firm has a 50 day moving average price of $1.58 and a 200 day moving average price of $2.56. The company has a market cap of $91.77 million, a PE ratio of -0.58 and a beta of 0.98.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.